114 related articles for article (PubMed ID: 38169272)
21. Design, synthesis and biological evaluation of novel 4-phenoxypyridine based 3-oxo-3,4-dihydroquinoxaline-2-carboxamide derivatives as potential c-Met kinase inhibitors.
Wang Z; Shi J; Zhu X; Zhao W; Gong Y; Hao X; Hou Y; Liu Y; Ding S; Liu J; Chen Y
Bioorg Chem; 2020 Dec; 105():104371. PubMed ID: 33075664
[TBL] [Abstract][Full Text] [Related]
22. Optimization of an Imidazo[1,2-
McCoull W; Boyd S; Brown MR; Coen M; Collingwood O; Davies NL; Doherty A; Fairley G; Goldberg K; Hardaker E; He G; Hennessy EJ; Hopcroft P; Hodgson G; Jackson A; Jiang X; Karmokar A; Lainé AL; Lindsay N; Mao Y; Markandu R; McMurray L; McLean N; Mooney L; Musgrove H; Nissink JWM; Pflug A; Reddy VP; Rawlins PB; Rivers E; Schimpl M; Smith GF; Tentarelli S; Travers J; Troup RI; Walton J; Wang C; Wilkinson S; Williamson B; Winter-Holt J; Yang D; Zheng Y; Zhu Q; Smith PD
J Med Chem; 2021 Sep; 64(18):13524-13539. PubMed ID: 34478292
[TBL] [Abstract][Full Text] [Related]
23. Design, synthesis and antitumor evaluation of novel 5-methylpyrazolo[1,5-a]pyrimidine derivatives as potential c-Met inhibitors.
Luo G; Ma Y; Liang X; Xie G; Luo Y; Zha D; Wang S; Yu L; Zheng X; Wu W; Zhang C
Bioorg Chem; 2020 Nov; 104():104356. PubMed ID: 33142417
[TBL] [Abstract][Full Text] [Related]
24. Design, synthesis and biological evaluation of 4-aniline quinazoline derivatives conjugated with hydrogen sulfide (H
Zheng YG; Zhang WQ; Meng L; Wu XQ; Zhang L; An L; Li CL; Gao CY; Xu L; Liu Y
Eur J Med Chem; 2020 Sep; 202():112522. PubMed ID: 32619886
[TBL] [Abstract][Full Text] [Related]
25. Discovery of 7H-pyrrolo[2,3-d]pyridine derivatives as potent FAK inhibitors: Design, synthesis, biological evaluation and molecular docking study.
Wang R; Zhao X; Yu S; Chen Y; Cui H; Wu T; Hao C; Zhao D; Cheng M
Bioorg Chem; 2020 Sep; 102():104092. PubMed ID: 32707280
[TBL] [Abstract][Full Text] [Related]
26. Structure-based discovery of novel 4-(2-fluorophenoxy)quinoline derivatives as c-Met inhibitors using isocyanide-involved multicomponent reactions.
Nan X; Li HJ; Fang SB; Li QY; Wu YC
Eur J Med Chem; 2020 May; 193():112241. PubMed ID: 32200199
[TBL] [Abstract][Full Text] [Related]
27. Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
Hou W; Ren Y; Zhang Z; Sun H; Ma Y; Yan B
Bioorg Med Chem; 2018 May; 26(8):1740-1750. PubMed ID: 29523467
[TBL] [Abstract][Full Text] [Related]
28. Identification of (S)-1-(2-(2,4-difluorophenyl)-4-oxothiazolidin-3-yl)-3-(4-((7-(3-(4-ethylpiperazin-1-yl)propoxy)-6-methoxyquinolin-4-yl)oxy)-3,5-difluorophenyl)urea as a potential anti-colorectal cancer agent.
Qi B; Wang F; He H; Fan M; Hu L; Xiong L; Gong G; Shi S; Song X
Eur J Med Chem; 2022 Sep; 239():114561. PubMed ID: 35763868
[TBL] [Abstract][Full Text] [Related]
29. Discovery of the selective and efficacious inhibitors of FLT3 mutations.
Zhi Y; Li B; Yao C; Li H; Chen P; Bao J; Qin T; Wang Y; Lu T; Lu S
Eur J Med Chem; 2018 Jul; 155():303-315. PubMed ID: 29894944
[TBL] [Abstract][Full Text] [Related]
30. Discovery and biological evaluation of N-(3-(7-((2-methoxy-4-(4-methylpiperazin-1-yl)phenyl)amino)-4-methyl-2-oxo-2H-pyrimido[4,5-d][1,3]oxazin-1(4H)-yl)phenyl)acrylamide as potent Bruton's tyrosine kinase inhibitors.
Lai MZ; Song PR; Dou D; Diao YY; Tong LJ; Zhang T; Xie H; Li HL; Ding J
Acta Pharmacol Sin; 2020 Mar; 41(3):415-422. PubMed ID: 31316181
[TBL] [Abstract][Full Text] [Related]
31. Development of a series of novel 4-anlinoquinazoline derivatives possessing quinazoline skeleton: Design, synthesis, EGFR kinase inhibitory efficacy, and evaluation of anticancer activities in vitro.
Chang J; Ren H; Zhao M; Chong Y; Zhao W; He Y; Zhao Y; Zhang H; Qi C
Eur J Med Chem; 2017 Sep; 138():669-688. PubMed ID: 28711702
[TBL] [Abstract][Full Text] [Related]
32. A New Series of Antileukemic Agents: Design, Synthesis, In Vitro and In Silico Evaluation of Thiazole-Based ABL1 Kinase Inhibitors.
Zeytün E; Altıntop MD; Sever B; Özdemir A; Ellakwa DE; Ocak Z; Ciftci HI; Otsuka M; Fujita M; Radwan MO
Anticancer Agents Med Chem; 2021; 21(9):1099-1109. PubMed ID: 32838725
[TBL] [Abstract][Full Text] [Related]
33. Design, synthesis, and biological evaluation of novel aminopyrimidinylisoindolines as AXL kinase inhibitors.
Choi MJ; Roh EJ; Hur W; Lee SH; Sim T; Oh CH; Lee SH; Kim JS; Yoo KH
Bioorg Med Chem Lett; 2018 Dec; 28(23-24):3761-3765. PubMed ID: 30340900
[TBL] [Abstract][Full Text] [Related]
34. Discovery of highly potent and selective EGFR
Yang T; Zhang W; Cao S; Sun S; Cai X; Xu L; Li P; Zheng Z; Li S
Eur J Med Chem; 2022 Jan; 228():113984. PubMed ID: 34794818
[TBL] [Abstract][Full Text] [Related]
35. Development of the phenylpyrazolo[3,4-
Lee HJ; Pham PC; Pei H; Lim B; Hyun SY; Baek B; Kim B; Kim Y; Kim MH; Kang NW; Min HY; Kim DD; Lee J; Lee HY
Theranostics; 2021; 11(4):1918-1936. PubMed ID: 33408789
[No Abstract] [Full Text] [Related]
36. Design, synthesis, biological evaluation and molecular docking study of novel thieno[3,2-d]pyrimidine derivatives as potent FAK inhibitors.
Wang R; Yu S; Zhao X; Chen Y; Yang B; Wu T; Hao C; Zhao D; Cheng M
Eur J Med Chem; 2020 Feb; 188():112024. PubMed ID: 31923858
[TBL] [Abstract][Full Text] [Related]
37. Discovery of potent and highly selective covalent inhibitors of Bruton's tyrosine kinase bearing triazine scaffold.
Teng Y; Lu X; Xiao M; Li Z; Zou Y; Ren S; Cheng Y; Luo G; Xiang H
Eur J Med Chem; 2020 Aug; 199():112339. PubMed ID: 32402933
[TBL] [Abstract][Full Text] [Related]
38. Click chemistry for improvement in selectivity of quinazoline-based kinase inhibitors for mutant epidermal growth factor receptors.
Song J; Jang S; Lee JW; Jung D; Lee S; Min KH
Bioorg Med Chem Lett; 2019 Feb; 29(3):477-480. PubMed ID: 30554954
[TBL] [Abstract][Full Text] [Related]
39. Discovery of novel 2-substituted-4-phenoxypyridine derivatives as potential antitumor agents.
Duan Y; Xu S; Xiong H; Wang L; Zhao B; Wang P; Wang C; Peng Y; Cai S; Luo R; Zheng P; Tang Q
Bioorg Med Chem Lett; 2018 Feb; 28(3):254-259. PubMed ID: 29317165
[TBL] [Abstract][Full Text] [Related]
40. Discovery of dual Axl/VEGF-R2 inhibitors as potential anti-angiogenic and anti-metastatic drugs for cancer chemotherapy.
Goff D; Zhang J; Heckrodt T; Yu J; Ding P; Singh R; Holland S; Li W; Irving M
Bioorg Med Chem Lett; 2017 Aug; 27(16):3766-3771. PubMed ID: 28711351
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]